Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Paul Yu
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Keros Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The project is researching BMP technology licensed to the company. The research results could make the licensed technology more/less valuable, thereby affecting the value of the financial interest of the company and the investigator. Given the Investigator's equity interest, the significant financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Molecular and cellular mechanisms of heterotopic ossification
PROJECT NARRATIVE This proposal asks how bone morphogenetic protein signals, which normally regulate the activity of progenitor cells involved in the repair of muscle, blood vessels, connective tissues, and bone, may become dysregulated to cause inappropriate bone formation in the human diseases of heterotopic ossification and fibrodysplasia ossificans progressiva. In addition to providing insights into the mechanism of these poorly understood processes, these studies may identify much needed novel approaches for their management. These mechanisms have relevance to a broader set of conditions in which inflammation and injury appear to lead to abnormal ossification in autoimmune, cardiac, and vascular disease.
Filed on March 07, 2017.
Tell us what you know about Paul Yu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Paul Yu filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | $20,000 - $39,999 |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | $20,000 - $39,999 |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | $10,000 - $19,999 |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | Value cannot be readily determined |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.